<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>vivolifescience.com/2012 IMMUNOGENICITY &#187; Vivo Life Science Immunogenicity</title>
	<atom:link href="http://www.vivolifescience.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.vivolifescience.com</link>
	<description>PH+4686511090</description>
	<lastBuildDate>Tue, 17 Jul 2012 13:49:53 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.3</generator>
		<item>
		<title>Chairman: Tudor Arvinte, Ph.D., Professor, Department of  Pharmaceutics, University of Geneva</title>
		<link>http://www.vivolifescience.com/2012/07/tudor-arvinte-ph-d-professor-department-of-pharmaceutics-university-of-geneva/</link>
		<comments>http://www.vivolifescience.com/2012/07/tudor-arvinte-ph-d-professor-department-of-pharmaceutics-university-of-geneva/#comments</comments>
		<pubDate>Fri, 06 Jul 2012 12:21:33 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Speakers]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[biophysics]]></category>
		<category><![CDATA[biotech company]]></category>
		<category><![CDATA[biotech products]]></category>
		<category><![CDATA[ciba geigy]]></category>
		<category><![CDATA[collaborations]]></category>
		<category><![CDATA[cornell university]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[düsseldorf germany]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[m university]]></category>
		<category><![CDATA[max planck]]></category>
		<category><![CDATA[max planck institute]]></category>
		<category><![CDATA[novartis]]></category>
		<category><![CDATA[peptides]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutics]]></category>
		<category><![CDATA[pharmacy university]]></category>
		<category><![CDATA[professor department]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[research positions]]></category>
		<category><![CDATA[school of pharmacy]]></category>
		<category><![CDATA[university of geneva]]></category>
		<category><![CDATA[vivo life sciencebiopharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1842</guid>
		<description><![CDATA[Tudor Arvinte was born in Romania in 1956, received his Ph.D. in biophysics from the University of Düsseldorf, Germany. He held research positions in Europe (Max-Planck-Institute, C.N R.S.) and in U.S.A. (Cornell University and Texas A&#38;M University). He joined Ciba-Geigy in England, and then Ciba-Geigy and Novartis in Basel where he was Head of Exploratory [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2012/07/tudor-arvinte-ph-d-professor-department-of-pharmaceutics-university-of-geneva/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Roger Bossé PhD, Global Product Leader – Alpha  Technologies, PerkinElmer Life Sciences &amp; Technology</title>
		<link>http://www.vivolifescience.com/2012/07/roger-bosse-phd-global-product-leader-%e2%80%93-alpha-technologies-perkinelmer-life-sciences-technology/</link>
		<comments>http://www.vivolifescience.com/2012/07/roger-bosse-phd-global-product-leader-%e2%80%93-alpha-technologies-perkinelmer-life-sciences-technology/#comments</comments>
		<pubDate>Fri, 06 Jul 2012 12:19:56 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Speakers]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1931</guid>
		<description><![CDATA[Roger Bossé holds a Ph.D. in Pharmacology from the University of Sherbrooke (Quebec, Canada). He completed his Post Doctoral training in Neuroendocrinology in Marc Caron’s lab (Cell Biology, Duke University, NC). Dr. Bossé joined BioSignal in 1996 as the R&#38;D Group Leader responsible for the development of the GPCR pipeline. Following the acquisition of BioSignal [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2012/07/roger-bosse-phd-global-product-leader-%e2%80%93-alpha-technologies-perkinelmer-life-sciences-technology/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Progress made by the Immunogenicity Prediction Action Program Area (IPAPA), part of the American Association of Pharmaceutical Scientists.</title>
		<link>http://www.vivolifescience.com/2012/04/progress-made-by-the-immunogenicity-prediction-action-program-area-ipapa-part-of-the-american-association-of-pharmaceutical-scientists/</link>
		<comments>http://www.vivolifescience.com/2012/04/progress-made-by-the-immunogenicity-prediction-action-program-area-ipapa-part-of-the-american-association-of-pharmaceutical-scientists/#comments</comments>
		<pubDate>Tue, 17 Apr 2012 07:56:55 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1914</guid>
		<description><![CDATA[The AAPS published newsletter of December 2011 describes their initiatives regarding advancements in unwanted immunogenicity prediction and understanding risk factors that lead to unwanted immunogenicity, including how they identify partner societies (American Association of Immunologists, European Immunogenicity Platform etc) to share, communicate and expand opportunities to develop Immunogenicity prediction strategies. In addition, they have conducted [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2012/04/progress-made-by-the-immunogenicity-prediction-action-program-area-ipapa-part-of-the-american-association-of-pharmaceutical-scientists/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>mAb’s and new ways to to anticipate and tackle immunogeniticy risks</title>
		<link>http://www.vivolifescience.com/2012/03/mab%e2%80%99s-and-new-ways-to-to-anticipate-and-tackle-immunogeniticy-risks/</link>
		<comments>http://www.vivolifescience.com/2012/03/mab%e2%80%99s-and-new-ways-to-to-anticipate-and-tackle-immunogeniticy-risks/#comments</comments>
		<pubDate>Mon, 26 Mar 2012 09:39:04 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1910</guid>
		<description><![CDATA[Since 1986, a number of therapeutic monoclonal antibodies have been approved by the US FDA and hundreds of therapies are undergoing clinical trials. More importantly, the market for such monoclonal antibodies has grown significantly and their sales growth rate of &#62; 35% far exceeds the &#60;8% sales for small-molecule drugs*. As an immunogenicity professional you [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2012/03/mab%e2%80%99s-and-new-ways-to-to-anticipate-and-tackle-immunogeniticy-risks/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Register to 2012 Immunogenicity &#8211; with IPI Campaign Code</title>
		<link>http://www.vivolifescience.com/2012/02/ipi/</link>
		<comments>http://www.vivolifescience.com/2012/02/ipi/#comments</comments>
		<pubDate>Tue, 21 Feb 2012 15:49:59 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1887</guid>
		<description><![CDATA[]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2012/02/ipi/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dr. Patrick Garidel, Head of Pharmaceutical Basic Development/Protein Science, Boehringer Ingelheim Pharma GmbH &amp; Co. KG</title>
		<link>http://www.vivolifescience.com/2012/02/dr-patrick-garidel-head-of-pharmaceutical-basic-developmentprotein-science-boehringer-ingelheim-pharma-gmbh-co-kg/</link>
		<comments>http://www.vivolifescience.com/2012/02/dr-patrick-garidel-head-of-pharmaceutical-basic-developmentprotein-science-boehringer-ingelheim-pharma-gmbh-co-kg/#comments</comments>
		<pubDate>Fri, 17 Feb 2012 14:46:03 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[boehringer ingelheim]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[desy hamburg]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[doc positions]]></category>
		<category><![CDATA[drug delivery systems]]></category>
		<category><![CDATA[halle saale]]></category>
		<category><![CDATA[hamburg germany]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[liposomes]]></category>
		<category><![CDATA[new york usa]]></category>
		<category><![CDATA[newark usa]]></category>
		<category><![CDATA[particle characterisation]]></category>
		<category><![CDATA[pharma gmbh]]></category>
		<category><![CDATA[physical chemistry]]></category>
		<category><![CDATA[platform technologies]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[protein purification]]></category>
		<category><![CDATA[protein science]]></category>
		<category><![CDATA[rutgers university newark]]></category>
		<category><![CDATA[structural biochemistry]]></category>
		<category><![CDATA[university halle]]></category>
		<category><![CDATA[university of kaiserslautern]]></category>
		<category><![CDATA[vivo life sciencebiopharmacy]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1883</guid>
		<description><![CDATA[His activities are focused on the development biologics from the downstream process to drug product (liquid and solid formulations). His expertise covers: protein purification, development of drug delivery systems (e.g. controlled release, liposomes) and formulations, primary packaging and devices, process development and transfer of biopharmaceuticals, bio-analytic and structural biochemistry, and particle characterisation. Additionally, he is [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2012/02/dr-patrick-garidel-head-of-pharmaceutical-basic-developmentprotein-science-boehringer-ingelheim-pharma-gmbh-co-kg/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development</title>
		<link>http://www.vivolifescience.com/2012/02/strategies-for-the-assessment-of-protein-aggregates-in-pharmaceutical-biotech-product-development/</link>
		<comments>http://www.vivolifescience.com/2012/02/strategies-for-the-assessment-of-protein-aggregates-in-pharmaceutical-biotech-product-development/#comments</comments>
		<pubDate>Tue, 14 Feb 2012 11:13:06 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[current state]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[pdf file]]></category>
		<category><![CDATA[protein aggregates]]></category>
		<category><![CDATA[protein characterization]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[protein therapeutics]]></category>
		<category><![CDATA[regard]]></category>
		<category><![CDATA[subcommittee]]></category>
		<category><![CDATA[vivo life sciencebiotech community]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1876</guid>
		<description><![CDATA[ABSTRACT Within the European Immunogenicity Platform (EIP) (http://www.e-i-p.eu), the Protein Characterization Subcommittee (EIP-PCS) has been established to discuss and exchange experience of protein characterization in relation to unwanted immunogenicity. In this commentary, we, as representatives of EIP-PCS, review the current state of methods for analysis of protein aggregates. Moreover, we elaborate on why these methods [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2012/02/strategies-for-the-assessment-of-protein-aggregates-in-pharmaceutical-biotech-product-development/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Christian Ross Pedersen, Novo Nordisk A/S</title>
		<link>http://www.vivolifescience.com/2012/02/christian-ross-pedersen-novo-nordisk-as/</link>
		<comments>http://www.vivolifescience.com/2012/02/christian-ross-pedersen-novo-nordisk-as/#comments</comments>
		<pubDate>Fri, 03 Feb 2012 09:29:29 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[pedersen]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[ross]]></category>
		<category><![CDATA[vivo life sciencenovo nordisk]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1840</guid>
		<description><![CDATA[]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2012/02/christian-ross-pedersen-novo-nordisk-as/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Robin Marsden, Scientist, Bioanalytical Lead, Ambrx Inc.</title>
		<link>http://www.vivolifescience.com/2012/02/robin-marsden-scientist-bioanalytical-lead-ambrx-inc/</link>
		<comments>http://www.vivolifescience.com/2012/02/robin-marsden-scientist-bioanalytical-lead-ambrx-inc/#comments</comments>
		<pubDate>Fri, 03 Feb 2012 09:28:32 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[ambrx inc]]></category>
		<category><![CDATA[amylin pharmaceuticals]]></category>
		<category><![CDATA[analytical laboratory]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[assays]]></category>
		<category><![CDATA[associate scientist]]></category>
		<category><![CDATA[california san diego]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[dendreon]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[dynavax]]></category>
		<category><![CDATA[elisa]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[immunotherapeutics]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[marsden]]></category>
		<category><![CDATA[matrix team]]></category>
		<category><![CDATA[nab]]></category>
		<category><![CDATA[pd]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[protein therapeutics]]></category>
		<category><![CDATA[risk assessments]]></category>
		<category><![CDATA[staff research associate]]></category>
		<category><![CDATA[university of california san diego]]></category>
		<category><![CDATA[validation]]></category>
		<category><![CDATA[vivo life science]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1838</guid>
		<description><![CDATA[Robin’s areas of expertise are expert bioanalytical method development, troubleshooting, and validation for PK, PD, and immunogenicity assays (ADA and cell-based NAb) in the context of stage-appropriate needs. He has worked at Ambrx, Inc since 2008, where he has lead the development, optimization, troubleshooting, and phase-appropriate validation of PK, PD and immunogenicity assays (ELISA and [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2012/02/robin-marsden-scientist-bioanalytical-lead-ambrx-inc/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dr. Andreas Seidl, Head of Bioanalytical Testing Facility and Head of Analytical Characterization, Sandoz Biopharmaceuticals</title>
		<link>http://www.vivolifescience.com/2012/02/dr-andreas-seidl-head-of-bioanalytical-testing-facility-and-head-of-analytical-characterization-sandoz-biopharmaceuticals/</link>
		<comments>http://www.vivolifescience.com/2012/02/dr-andreas-seidl-head-of-bioanalytical-testing-facility-and-head-of-analytical-characterization-sandoz-biopharmaceuticals/#comments</comments>
		<pubDate>Fri, 03 Feb 2012 09:27:28 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Speakers]]></category>
		<category><![CDATA[analytics]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[biopharmaceutical]]></category>
		<category><![CDATA[biopharmaceuticals]]></category>
		<category><![CDATA[characterization]]></category>
		<category><![CDATA[chemist]]></category>
		<category><![CDATA[comparability]]></category>
		<category><![CDATA[constance germany]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[ec]]></category>
		<category><![CDATA[ema]]></category>
		<category><![CDATA[epoetin alfa]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[market approval]]></category>
		<category><![CDATA[oberhaching]]></category>
		<category><![CDATA[pharmaceutical development]]></category>
		<category><![CDATA[protein chemistry]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[quality control]]></category>
		<category><![CDATA[reference products]]></category>
		<category><![CDATA[sandoz]]></category>
		<category><![CDATA[seidl]]></category>
		<category><![CDATA[test facility]]></category>
		<category><![CDATA[vivo life scienceanalytical biochemistry]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1836</guid>
		<description><![CDATA[Andreas Seidl is heading the Bioanalytical Test Facility and the Analytical Characterization departments of Sandoz Biopharmaceutical development Oberhaching/Germany. At Sandoz he developed concepts for demonstration of physicochemical and biological comparability of biosimilars in comparison with their originator reference products as well as after process changes. During his career at Sandoz he hold different positions in [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2012/02/dr-andreas-seidl-head-of-bioanalytical-testing-facility-and-head-of-analytical-characterization-sandoz-biopharmaceuticals/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Juliana Bessa, PhD, pRED Basel, SMR-DT,  F. Hoffmann-La Roche Ltd</title>
		<link>http://www.vivolifescience.com/2012/02/juliana-bessa-phd-pred-basel-smr-dt-f-hoffmann-la-roche-ltd/</link>
		<comments>http://www.vivolifescience.com/2012/02/juliana-bessa-phd-pred-basel-smr-dt-f-hoffmann-la-roche-ltd/#comments</comments>
		<pubDate>Fri, 03 Feb 2012 09:20:00 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Speakers]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[diploma work]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[faculty of medicine]]></category>
		<category><![CDATA[heart institute]]></category>
		<category><![CDATA[hoffmann la roche]]></category>
		<category><![CDATA[human igg]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[immunological aspects]]></category>
		<category><![CDATA[institute faculty]]></category>
		<category><![CDATA[kalil]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[martin bachmann]]></category>
		<category><![CDATA[pharmaceutical technology]]></category>
		<category><![CDATA[phd programme]]></category>
		<category><![CDATA[postdoc]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[smr]]></category>
		<category><![CDATA[therapeutic antibodies]]></category>
		<category><![CDATA[traineeship]]></category>
		<category><![CDATA[transgenic animals]]></category>
		<category><![CDATA[vaccine design]]></category>
		<category><![CDATA[vivo life sciencebessa]]></category>
		<category><![CDATA[vlps]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1834</guid>
		<description><![CDATA[Juliana Bessa has being working as a Postdoc in the characterization of the human IgG transgenic animals as a tool to predict immunogenicity of human therapeutic antibodies. Juliana is Brazilian and first came to to Switzerland in 2000 for 6 months, when she undertook a diploma work at the Institute of Pharmaceutical Technology in Basel. [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2012/02/juliana-bessa-phd-pred-basel-smr-dt-f-hoffmann-la-roche-ltd/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Impact of product-related factors on immunogenicity of biotherapeutics</title>
		<link>http://www.vivolifescience.com/2012/01/impact-of-product-related-factors-on-immunogenicity-of-biotherapeutics/</link>
		<comments>http://www.vivolifescience.com/2012/01/impact-of-product-related-factors-on-immunogenicity-of-biotherapeutics/#comments</comments>
		<pubDate>Mon, 23 Jan 2012 09:23:59 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[completeness]]></category>
		<category><![CDATA[container closure]]></category>
		<category><![CDATA[current state]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[doi]]></category>
		<category><![CDATA[excipients]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[molecule design]]></category>
		<category><![CDATA[new article]]></category>
		<category><![CDATA[onlinelibrary]]></category>
		<category><![CDATA[patient characteristics]]></category>
		<category><![CDATA[pfizer]]></category>
		<category><![CDATA[pfizer corporation]]></category>
		<category><![CDATA[preclinical data]]></category>
		<category><![CDATA[product development scientist]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[protein therapeutics]]></category>
		<category><![CDATA[relevant cases]]></category>
		<category><![CDATA[research fellow]]></category>
		<category><![CDATA[satish kumar]]></category>
		<category><![CDATA[vivo life scienceadas]]></category>
		<category><![CDATA[wiley]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1828</guid>
		<description><![CDATA[New article by Satish Kumar Singh, Ph.D, Research Fellow, Pfizer Corporation released in December 2012: “Impact of product-related factors on immunogenicity”. In the words of author, “the objective of this review was to provide the product development scientist a critical look at the current state of knowledge connecting CMC aspects and product-related clinical immunogenicity. Relevant [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2012/01/impact-of-product-related-factors-on-immunogenicity-of-biotherapeutics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Maureen Deehan, Head of Pharmacology, Novimmune SA</title>
		<link>http://www.vivolifescience.com/2011/12/maureen-deehan-head-of-pharmacology-novimmune-sa/</link>
		<comments>http://www.vivolifescience.com/2011/12/maureen-deehan-head-of-pharmacology-novimmune-sa/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 09:46:55 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Speakers]]></category>
		<category><![CDATA[6 years]]></category>
		<category><![CDATA[academic career]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[assays]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[experimental science]]></category>
		<category><![CDATA[faculty of medicine]]></category>
		<category><![CDATA[faculty of medicine university of glasgow]]></category>
		<category><![CDATA[geneva switzerland]]></category>
		<category><![CDATA[graduation]]></category>
		<category><![CDATA[immune cell]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[medicine department]]></category>
		<category><![CDATA[medicine university]]></category>
		<category><![CDATA[novimmune]]></category>
		<category><![CDATA[pharmacokinetics]]></category>
		<category><![CDATA[pharmacology]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[target validation]]></category>
		<category><![CDATA[translational medicine]]></category>
		<category><![CDATA[university of glasgow]]></category>
		<category><![CDATA[university of glasgow scotland]]></category>
		<category><![CDATA[vitro]]></category>
		<category><![CDATA[vivo life science]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1753</guid>
		<description><![CDATA[Dr. Maureen Deehan is Head of Pharmacology, in the Experimental Science &#38; Translational Medicine Department at NovImmune, in Geneva, Switzerland. The group supports preclinical and clinical programs by developing assays for target validation, in vitro pharmacology, pharmacokinetics, immunogenicity, safety, and biomarkers. Following graduation from the Faculty of Medicine, University of Glasgow, Scotland she pursued an [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2011/12/maureen-deehan-head-of-pharmacology-novimmune-sa/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Birgit Reipert, PhD &amp; Director Department of Immunology, Baxter BioScience (Franchise Hemophilia/Hematology)</title>
		<link>http://www.vivolifescience.com/2011/12/birgit-reipert-phd-director-department-of-immunology-baxter-bioscience-franchise-hemophiliahematology/</link>
		<comments>http://www.vivolifescience.com/2011/12/birgit-reipert-phd-director-department-of-immunology-baxter-bioscience-franchise-hemophiliahematology/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 09:42:17 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[baxter bioscience]]></category>
		<category><![CDATA[berlin germany]]></category>
		<category><![CDATA[cancer research]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[ernst moritz arndt]]></category>
		<category><![CDATA[greifswald germany]]></category>
		<category><![CDATA[hematology]]></category>
		<category><![CDATA[hemophilia]]></category>
		<category><![CDATA[immune responses]]></category>
		<category><![CDATA[immuno ag]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[lectureship]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[medical immunology]]></category>
		<category><![CDATA[medical university]]></category>
		<category><![CDATA[paterson institute]]></category>
		<category><![CDATA[phd director]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[therapeutic proteins]]></category>
		<category><![CDATA[university greifswald]]></category>
		<category><![CDATA[university of vienna]]></category>
		<category><![CDATA[vienna austria]]></category>
		<category><![CDATA[vivo life sciencearndt university]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1819</guid>
		<description><![CDATA[Birgit Reipert, PhD, is Director of the Department of Immunology within the Franchise Hemophilia/Hematology at Baxter BioScience. In addition, she has got a lectureship at the Medical University of Vienna (Austria). She received her PhD from the Ernst-Moritz Arndt University, Greifswald (Germany), and postdoctoral training at the Institute for Medical Immunology at the Charitè, Berlin [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2011/12/birgit-reipert-phd-director-department-of-immunology-baxter-bioscience-franchise-hemophiliahematology/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Harald Petry, PhD. Director of Research and Development, AMT Biopharma</title>
		<link>http://www.vivolifescience.com/2011/12/harald-petry-phd-director-of-research-and-development-amt-biopharma/</link>
		<comments>http://www.vivolifescience.com/2011/12/harald-petry-phd-director-of-research-and-development-amt-biopharma/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 07:48:14 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Speakers]]></category>
		<category><![CDATA[10 years]]></category>
		<category><![CDATA[academic research]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[berlex biosciences]]></category>
		<category><![CDATA[biopharma]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[director of research]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[gene therapy]]></category>
		<category><![CDATA[gmbh germany]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[leadership responsibility]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[nbsp]]></category>
		<category><![CDATA[netherlands]]></category>
		<category><![CDATA[petry]]></category>
		<category><![CDATA[pharmaceutical research]]></category>
		<category><![CDATA[phd director]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[research and development]]></category>
		<category><![CDATA[vivo life science]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1750</guid>
		<description><![CDATA[Dr. Petry joined AMT in May 2007 as Director of the Research and Development. He has worked in the area of gene therapy for more than 15 years and has extensive experience in pharmaceutical research. After his PhD he built up a career in academic research; for the last 10 years he has worked at [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2011/12/harald-petry-phd-director-of-research-and-development-amt-biopharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Erwin L Roggen, Science Manager Predictive Technology, Novozymes</title>
		<link>http://www.vivolifescience.com/2011/12/erwin-l-roggen-science-manager-predictive-technology-novozymes/</link>
		<comments>http://www.vivolifescience.com/2011/12/erwin-l-roggen-science-manager-predictive-technology-novozymes/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 07:46:43 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Speakers]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[biotech projects]]></category>
		<category><![CDATA[book chapters]]></category>
		<category><![CDATA[cell biology]]></category>
		<category><![CDATA[co author]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[editorial board]]></category>
		<category><![CDATA[european framework]]></category>
		<category><![CDATA[frontiers]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[molecular biology]]></category>
		<category><![CDATA[novozymes]]></category>
		<category><![CDATA[postdoctoral fellowships]]></category>
		<category><![CDATA[predictive technology]]></category>
		<category><![CDATA[protein chemistry]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[roggen]]></category>
		<category><![CDATA[safety assessment]]></category>
		<category><![CDATA[science manager]]></category>
		<category><![CDATA[scientific advisory board]]></category>
		<category><![CDATA[sot]]></category>
		<category><![CDATA[toxicological sciences]]></category>
		<category><![CDATA[toxicology in vitro]]></category>
		<category><![CDATA[university of antwerp]]></category>
		<category><![CDATA[vivo life science]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1751</guid>
		<description><![CDATA[Dr. Erwin L. Roggen is Manager for In Vitro Toxicology at Novozymes. He received his doctorate in Biochemistry from the University of Antwerp (1984). Four postdoctoral fellowships allowed him to expand his expertise into the areas of protein chemistry, molecular biology, immunology, cell biology and management. He also works as a project manager at 3RsMC. [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2011/12/erwin-l-roggen-science-manager-predictive-technology-novozymes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Satish K. Singh, Ph.D, Research Fellow, Pfizer Corporation Pharmaceutical R &amp; D</title>
		<link>http://www.vivolifescience.com/2011/12/satish-k-singh-ph-d-research-fellow-pfizer-corporation-pharmaceutical-r-d/</link>
		<comments>http://www.vivolifescience.com/2011/12/satish-k-singh-ph-d-research-fellow-pfizer-corporation-pharmaceutical-r-d/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 07:45:53 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Speakers]]></category>
		<category><![CDATA[adjunct professor]]></category>
		<category><![CDATA[aggregation]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[b tech]]></category>
		<category><![CDATA[biomolecules]]></category>
		<category><![CDATA[chemistry techniques]]></category>
		<category><![CDATA[current research interests]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[indian institute of technology]]></category>
		<category><![CDATA[industry scientists]]></category>
		<category><![CDATA[kansas state university]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[oral dosage]]></category>
		<category><![CDATA[particulates]]></category>
		<category><![CDATA[pfizer]]></category>
		<category><![CDATA[pfizer corporation]]></category>
		<category><![CDATA[pharmaceutical chemistry]]></category>
		<category><![CDATA[physical chemistry of macromolecules]]></category>
		<category><![CDATA[propensity]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[research fellow]]></category>
		<category><![CDATA[satish]]></category>
		<category><![CDATA[uppsala university sweden]]></category>
		<category><![CDATA[vivo life science]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1747</guid>
		<description><![CDATA[Dr. Satish Singh is a Research Fellow, Pfizer Corporation, Pharmaceutical R &#38; D. His responsibilities include leading formulation, process and product development activities for biologics, including vaccines, in the organization. He has more than 20 years experience in the industry in product development activities ranging from oral dosage forms to ophthalmics and parenterals, encompassing small [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2011/12/satish-k-singh-ph-d-research-fellow-pfizer-corporation-pharmaceutical-r-d/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Linlin Luo, PhD in Biochemistry, Research Investigator II, Bristol-Myers Squibb Company (TBC)</title>
		<link>http://www.vivolifescience.com/2011/12/zoe-tzogas-research-scientist-bristol-myers-squibb-tbc/</link>
		<comments>http://www.vivolifescience.com/2011/12/zoe-tzogas-research-scientist-bristol-myers-squibb-tbc/#comments</comments>
		<pubDate>Tue, 13 Dec 2011 14:28:20 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1812</guid>
		<description><![CDATA[]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2011/12/zoe-tzogas-research-scientist-bristol-myers-squibb-tbc/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dr Pierre Cortez, Head Biologics &amp; Biomarkers, Sanofi-Aventis (TBC)</title>
		<link>http://www.vivolifescience.com/2011/12/dr-pierre-cortez-head-biologics-biomarkers-sanofi-aventis-tbc/</link>
		<comments>http://www.vivolifescience.com/2011/12/dr-pierre-cortez-head-biologics-biomarkers-sanofi-aventis-tbc/#comments</comments>
		<pubDate>Tue, 13 Dec 2011 14:27:45 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1810</guid>
		<description><![CDATA[]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2011/12/dr-pierre-cortez-head-biologics-biomarkers-sanofi-aventis-tbc/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>David Meininger, Senior Director Biologics Discovery, Merck (TBC)</title>
		<link>http://www.vivolifescience.com/2011/12/david-meininger-senior-director-biologics-discovery-merck-tbc/</link>
		<comments>http://www.vivolifescience.com/2011/12/david-meininger-senior-director-biologics-discovery-merck-tbc/#comments</comments>
		<pubDate>Tue, 13 Dec 2011 14:25:27 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1805</guid>
		<description><![CDATA[Dr. Meininger joined Merck in 2011 as Head of Protein Sciences. He serves as a member of the Biologics RLC, is co-champion of the bispecifics technology program and plays a strategic function in support of the Ambrx and Zymeworks partnerships. Dr. Meininger is responsible for oversight of lead generation efforts in support of biotherapeutic programs [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2011/12/david-meininger-senior-director-biologics-discovery-merck-tbc/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dr. Daniela Verthelyi, M.D., Ph.D., Chief, Laboratory of Immunology, Division of Therapeutic Proteins, OBP, CDER, FDA (US)</title>
		<link>http://www.vivolifescience.com/2011/12/dr-daniela-verthelyi-m-d-ph-d-chief-laboratory-of-immunology-division-of-therapeutic-proteins-obp-cder-fda-us-preliminary-confirmed/</link>
		<comments>http://www.vivolifescience.com/2011/12/dr-daniela-verthelyi-m-d-ph-d-chief-laboratory-of-immunology-division-of-therapeutic-proteins-obp-cder-fda-us-preliminary-confirmed/#comments</comments>
		<pubDate>Tue, 13 Dec 2011 14:20:54 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Speakers]]></category>
		<category><![CDATA[agonists]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[cder fda]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[disease models]]></category>
		<category><![CDATA[fellowship training]]></category>
		<category><![CDATA[immune function]]></category>
		<category><![CDATA[immunocompromised patient]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[impurities]]></category>
		<category><![CDATA[innate immune response]]></category>
		<category><![CDATA[interest group]]></category>
		<category><![CDATA[laboratory sciences]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[modulators]]></category>
		<category><![CDATA[novel chemistry]]></category>
		<category><![CDATA[odn]]></category>
		<category><![CDATA[patient populations]]></category>
		<category><![CDATA[primate model]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[sciences award]]></category>
		<category><![CDATA[therapeutic proteins]]></category>
		<category><![CDATA[university of buenos aires]]></category>
		<category><![CDATA[vaccine adjuvants]]></category>
		<category><![CDATA[viral encephalitis]]></category>
		<category><![CDATA[vivo life science]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1801</guid>
		<description><![CDATA[Dr. Verthelyi received her MD from the University of Buenos Aires and a PhD from the Virginia Tech in USA, and then completed a fellowship training in Immunology at the Section in Retroviral Immunology of the Center for Biologics Evaluation and Research of the FDA before joining the Laboratory of Immunology of Division of Therapeutic [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2011/12/dr-daniela-verthelyi-m-d-ph-d-chief-laboratory-of-immunology-division-of-therapeutic-proteins-obp-cder-fda-us-preliminary-confirmed/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Igor Vostiar, Principal Scientist, Novartis</title>
		<link>http://www.vivolifescience.com/2011/12/igor-vostiar-principal-scientist-novartis/</link>
		<comments>http://www.vivolifescience.com/2011/12/igor-vostiar-principal-scientist-novartis/#comments</comments>
		<pubDate>Mon, 12 Dec 2011 10:51:50 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Speakers]]></category>
		<category><![CDATA[academic background]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[assay development]]></category>
		<category><![CDATA[assays]]></category>
		<category><![CDATA[biochemistry]]></category>
		<category><![CDATA[biotechnology]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[development flow]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[elisa development]]></category>
		<category><![CDATA[flow cytometry]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[linköpings universitet]]></category>
		<category><![CDATA[nbsp]]></category>
		<category><![CDATA[novartis]]></category>
		<category><![CDATA[pnnl]]></category>
		<category><![CDATA[postdoctoral researcher]]></category>
		<category><![CDATA[principal scientist]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[research scientist]]></category>
		<category><![CDATA[surface plasmon resonance]]></category>
		<category><![CDATA[vivo life science]]></category>
		<category><![CDATA[xencor]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1769</guid>
		<description><![CDATA[Igor has been working at Novartis since july 2008. Before that, he worked as a scientist at Xencor in the fields of PK/PD assay development, flow cytometry, cell-based assay development and surface plasmon resonance (biacore) (2006-2008). He was a postdoctoral researcher at PNNL for one year, working with ELISA development and multiplex bead-based assays and [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2011/12/igor-vostiar-principal-scientist-novartis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prof. Dr. Wim Jiskoot, Professor of drug delivery, Biologics Formulation Group, University of Leiden</title>
		<link>http://www.vivolifescience.com/2011/12/prof-dr-wim-jiskoot-professor-of-drug-delivery-biologics-formulation-group-university-of-leiden/</link>
		<comments>http://www.vivolifescience.com/2011/12/prof-dr-wim-jiskoot-professor-of-drug-delivery-biologics-formulation-group-university-of-leiden/#comments</comments>
		<pubDate>Mon, 12 Dec 2011 10:48:23 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[bilthoven]]></category>
		<category><![CDATA[biophysical techniques]]></category>
		<category><![CDATA[current research]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[drug delivery technology]]></category>
		<category><![CDATA[formulation group]]></category>
		<category><![CDATA[full professor]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[ligand interactions]]></category>
		<category><![CDATA[monoclonal antibodies]]></category>
		<category><![CDATA[national institute of public health]]></category>
		<category><![CDATA[pharmaceutical aspects]]></category>
		<category><![CDATA[pharmaceutics]]></category>
		<category><![CDATA[phd degree]]></category>
		<category><![CDATA[postdoctoral fellow]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[research platform]]></category>
		<category><![CDATA[therapeutic proteins]]></category>
		<category><![CDATA[university of leiden]]></category>
		<category><![CDATA[utrecht university]]></category>
		<category><![CDATA[vaccine delivery]]></category>
		<category><![CDATA[vaccine development]]></category>
		<category><![CDATA[vivo life science]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1749</guid>
		<description><![CDATA[Wim Jiskoot graduated as a pharmacist in 1987 and received his PhD degree in 1991 at Utrecht University on pharmaceutical aspects of monoclonal antibodies. As a postdoctoral fellow at the University of Utah (1991-1993) he studied protein-ligand interactions using biophysical techniques. From 1994-1998 he was head of the Department of Bacterial Vaccine Development at the [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2011/12/prof-dr-wim-jiskoot-professor-of-drug-delivery-biologics-formulation-group-university-of-leiden/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Robin Thorpe, Head, Biotherapeutics Group, National Institute for Biological Standards and Control (NIBSC)</title>
		<link>http://www.vivolifescience.com/2011/12/robin-thorpe-head-biotherapeutics-group-national-institute-for-biological-standards-and-control-nibsc/</link>
		<comments>http://www.vivolifescience.com/2011/12/robin-thorpe-head-biotherapeutics-group-national-institute-for-biological-standards-and-control-nibsc/#comments</comments>
		<pubDate>Mon, 12 Dec 2011 10:47:41 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Speakers]]></category>
		<category><![CDATA[analytical chemistry]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[associate editor]]></category>
		<category><![CDATA[bioassays]]></category>
		<category><![CDATA[biological products]]></category>
		<category><![CDATA[biological standards]]></category>
		<category><![CDATA[biotechnological products]]></category>
		<category><![CDATA[british pharmacopoeia]]></category>
		<category><![CDATA[chemokines]]></category>
		<category><![CDATA[chm]]></category>
		<category><![CDATA[chmp]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[editorial board member]]></category>
		<category><![CDATA[european pharmacopoeia]]></category>
		<category><![CDATA[expert advisory group]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[international cytokine society]]></category>
		<category><![CDATA[journal of immunological methods]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[monoclonal antibodies]]></category>
		<category><![CDATA[nomenclature committee]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[scientific journals]]></category>
		<category><![CDATA[standardisation]]></category>
		<category><![CDATA[vivo life science]]></category>

		<guid isPermaLink="false">http://www.vivolifescience.com/?p=1754</guid>
		<description><![CDATA[Robin Thorpe PhD, FRCPath, is Head of the Biotherapeutics Group at the National Institute for Biological Standards and Control (NIBSC). Recent interests include the unwanted immunogenicity of biologicals, development of improved bioassays for cytokines, the immunology of monoclonal antibodies and cytokine contamination of biological products. He attends meetings of the Biologicals Working Party &#38; Biosimilars [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2011/12/robin-thorpe-head-biotherapeutics-group-national-institute-for-biological-standards-and-control-nibsc/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Welcome to 2012 IMMUNOGENICITY</title>
		<link>http://www.vivolifescience.com/2011/09/welcome-to-2012-immunogenicity/</link>
		<comments>http://www.vivolifescience.com/2011/09/welcome-to-2012-immunogenicity/#comments</comments>
		<pubDate>Wed, 07 Sep 2011 11:50:12 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Events]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[biopharmaceutical]]></category>
		<category><![CDATA[clinical relevance]]></category>
		<category><![CDATA[core areas]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[patient safety]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[regulatory requirements]]></category>
		<category><![CDATA[vivo life science]]></category>

		<guid isPermaLink="false">http://wp-30.systeamhalmstad.se/?p=1613</guid>
		<description><![CDATA[The 2012 Immunogenicity will gather global biopharmaceutical, institutes, scientific experts and regulators striving to tackle unwanted immunogenicity which poses threats to patient safety and to scientific development. The comprehensive program is divided into 2 core areas. The first focuses on Immunogenicity Awareness and Assessment of Clinical Relevance. The second gives practical insights on Detecting, Determining [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2011/09/welcome-to-2012-immunogenicity/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Key issues not to miss this conference</title>
		<link>http://www.vivolifescience.com/2011/09/key-issues-not-to-miss/</link>
		<comments>http://www.vivolifescience.com/2011/09/key-issues-not-to-miss/#comments</comments>
		<pubDate>Wed, 07 Sep 2011 11:27:41 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[amp]]></category>
		<category><![CDATA[antibody immunogenicity]]></category>
		<category><![CDATA[antigenicity]]></category>
		<category><![CDATA[antigenicity prediction]]></category>
		<category><![CDATA[ascites production]]></category>
		<category><![CDATA[assay development]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[continuous compliance]]></category>
		<category><![CDATA[cost efficiency]]></category>
		<category><![CDATA[define immunogenic]]></category>
		<category><![CDATA[define immunogenicity]]></category>
		<category><![CDATA[discovery life sciences immunogenicity testing]]></category>
		<category><![CDATA[fda]]></category>
		<category><![CDATA[guidance]]></category>
		<category><![CDATA[immunogen definition]]></category>
		<category><![CDATA[immunogenic]]></category>
		<category><![CDATA[immunogenic definition]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[immunogenicity assay]]></category>
		<category><![CDATA[immunogenicity assays]]></category>
		<category><![CDATA[immunogenicity assessment immunogenicity 2012]]></category>
		<category><![CDATA[immunogenicity case studies]]></category>
		<category><![CDATA[immunogenicity conference]]></category>
		<category><![CDATA[immunogenicity definition]]></category>
		<category><![CDATA[immunogenicity of therapeutic proteins]]></category>
		<category><![CDATA[immunogenicity prediction]]></category>
		<category><![CDATA[immunogenicity test]]></category>
		<category><![CDATA[immunogens]]></category>
		<category><![CDATA[life science company]]></category>
		<category><![CDATA[methodology]]></category>
		<category><![CDATA[protein immunogenicity]]></category>
		<category><![CDATA[regulatory approaches]]></category>
		<category><![CDATA[screening strategies]]></category>
		<category><![CDATA[vivo life science]]></category>

		<guid isPermaLink="false">http://wp-30.systeamhalmstad.se/?p=1620</guid>
		<description><![CDATA[Immunogenicity assessment: best practice to increase accuracy and cost-efficiency during pre-clinical and clinical trials FDA &#38; EMEA Regulatory Approaches: FDA and EMEA Risk Balanced guidance and regulatory matters to ensure continuous compliance. Assay development plan &#38; methodology: all key issues to improve bioassays efficiency, such as detecting ATAs, validating Assays and use of statistics Immunogenicity [...]]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2011/09/key-issues-not-to-miss/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Call for Speakers</title>
		<link>http://www.vivolifescience.com/2011/08/call-for-speakers-2/</link>
		<comments>http://www.vivolifescience.com/2011/08/call-for-speakers-2/#comments</comments>
		<pubDate>Thu, 25 Aug 2011 14:52:40 +0000</pubDate>
		<dc:creator>robert</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://www.nfcsymposium.com/?p=1584</guid>
		<description><![CDATA[]]></description>
		<wfw:commentRss>http://www.vivolifescience.com/2011/08/call-for-speakers-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
